Virtus KAR Health Sciences FundRCGHX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$89.8M
Expense ratio
2.16%
1-year return
+6.4%
3 years, a year
-6.1%
5 years, a year
-5.6%
Holdings
24
What it aims to do.
The fund seeks long-term capital appreciation .
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co. | 13.30% |
| MCK Mckesson Corp. | 5.57% |
| VRTX Vertex Pharmaceuticals Incorporated | 5.09% |
| ABBV AbbVie Inc. | 5.09% |
| MRK Merck & Co., Inc | 5.05% |
| ISRG Intuitive Surgical Inc. | 4.80% |
| WST West Pharmaceutical Services Incorporated | 4.40% |
| IDXX IDEXX Laboratories Inc. | 4.29% |
| MTD Mettler-Toledo International Inc | 4.20% |
| COO The Cooper Companies, Inc. | 4.04% |
More on RCGHX.
- RCGHX overview
- RCGHX holdings
- RCGHX risk
- RCGHX costs
- RCGHX money in and out
- RCGHX share classes
- Compare RCGHX with other funds
Returns after fees, from the fund's SEC filings up to Dec 2025. Past returns are not a promise. Not financial advice.